Wednesday 25 June 2025, 17:00 - 18:00, Room: Copacabana
DRY EYE - Inflammatory pathways in ocular surface disease and novel treatments
Moderator: Yuka OKADA
Session supported by
| 17:00 | Role of TRP channels for neurotrophic keratopathy |
| OKADA Y | |
| 17:08 | Discussions & Questions |
| 17:12 | Immune Response in Meibomian Gland Dysfunction |
| YOU J | |
| 17:20 | Discussions & Questions |
| 17:24 | Corneal Nerves as Therapeutic Targets in Ocular Surface Diseases |
| YANAI R | |
| 17:32 | Discussions & Questions |
| 17:36 | Anti-Inflammatory Properties of Platelet-Rich Plasma for Inflammatory Ocular Surface Diseases |
| SURA A | |
| 17:44 | Discussions & Questions |
| 17:48 | Ocular surface as a target of inflammation: an underappreciated cause of irreversible vision loss |
| MATOS K | |
| 17:56 | Discussions & Questions |
| 18:00 | End of Session |
Session supported by
Thursday 26 June 2025, 14:15 - 15:15, Room: Copacabana
Drug Delivery and Emerging Therapies Moderators: Khayyam DURRANI, Victor LLORENS BELLES, Quan Dong NGUYEN
Session supported by
| 14:15 | Potential Role of Tissue Plasminogen Activator (TPA) in the Management of Uveitis |
| SPENCER D | |
| 14:22 | Potential Role of Regenerative Medicine in Treating the Complications of Ocular Inflammatory Diseases |
| DURRANI K | |
| 14:29 | Potential Role of Vamikivart in UME: Insights from the SANDCAT/MEERCAT Studies |
| LLORENS BELLES V | |
| 14:36 | Potential Role of OCS-01 in UME: What May We Learn from the LEOPARD Study |
| OR C | |
| 14:43 | Cell Therapy for Non-Infectious Uveitis: Insights into the PEACOCX Study |
| HUNG JH | |
| 14:50 | Laquinimod as Potential Therapeutic Approach for Non-Infectious Uveitis: What Have We Learned from the LION Study |
| EL FEQI D | |
| 14:57 | Can JAK-Inhibitor Be First-Line Non-Steroidal Therapy for Non-infectious Uveitis? |
| DACEY M | |
| 15:04 | Discussion |
| 15:15 | End of Session |
Session supported by